Combined hormonal contraceptives and venous thromboembolism: Putting the risks into perspective

Obstetrics and Gynecology

Volumn 119, Issue 5, 2012, Pages 1039-1044

  Raymond, Elizabeth G ^a,b,c   Burke, Anne E ^a,b,c   Espey, Eve ^a,b,c  

^a GYNUITY HEALTH PROJECTS   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE; ETHINYLESTRADIOL; GESTAGEN; NORELGESTROMIN; ORAL CONTRACEPTIVE AGENT;

ACNE; CANCER RISK; COLORECTAL CANCER; DYSMENORRHEA; ENDOMETRIOSIS; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEREDITY; HUMAN; INCIDENCE; MATERNAL MORTALITY; MEDICAL RECORD REVIEW; MENSTRUATION DISORDER; OBESITY; OVARY CANCER; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; UTERUS CANCER; VENOUS THROMBOEMBOLISM;

ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, HORMONAL; DRUG LABELING; ETHINYL ESTRADIOL; FEMALE; HUMANS; NORGESTREL; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 84860193714     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31825194ca     Document Type: Review

References (33)

1. Hannaford PC. Epidemiology of the contraceptive pill and venous thromboembolism. Thromb Res 2011;127:S30-4.
2. Dinger J, Assmann A, Mö hner S, Minh TD. Risk of venous thromboembolism and the use of dienogest-and drospirenonecontaining oral contraceptives: results from a German casecontrol study. Journal of family planning and reproductive health care 2010;36:123-9.
3. Dinger JC, Heinemann LA, Kü hl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54. (Pubitemid 46551071)
4. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol 2007;110:587-93. (Pubitemid 47359582)
5. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921.
6. Lidegaard O, Nielsen LH, Skovlund CW, Skjeldestad FE, Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343: d6423.
7. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151.
8. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011; 342:d2139.
9. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 2011;183: E1319-25.
10. FDA Office of Surveillance and Epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. 2011. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf. Retrieved January 1, 2012.
11. Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception 2010;81:16-21.
12. Jick SS, Hagberg KW, Kaye JA. ORTHO EVRA and venous thromboembolism: an update. Contraception 2010;81:452-3.
13. Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception 2010; 81:408-13.
14. Grimes DA. Epidemiologic research using administrative databases: garbage in, garbage out. Obstet Gynecol 2010;116: 1018-9.
15. Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjønneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol 2010;63:223-8.
16. Archer DF, Lasa IL. Tailoring combination oral contraceptives to the individual woman. J Womens Health (Larchmt) 2011; 20:879-91.
17. Pyke S, Julious SA, Day S, O'Kelly M, Todd S, Matcham J, et al. The potential for bias in reporting of industry-sponsored clinical trials. Pharm Stat 2011;10:74-9.
18. Tchaikovski SN, Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res 2010;126:5-11.
19. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancyrelated mortality in the United States, 1998 to 2005. Obstet Gynecol 2010;116:1302-9.
20. Bruce FC, Berg CJ, Hornbrook MC, Whitlock EP, Callaghan WM, Bachman DJ, et al. Maternal morbidity rates in a managed care population. Obstet Gynecol 2008;111:1089-95. (Pubitemid 351620342)
21. Martin JA, Hamilton BE, Ventura SJ, Osterman MJK, Kirmeyer S, Mathews TJ, et al. Births: final data for 2009. Natl Vital Stat Rep 2011;60.
22. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year populationbased study. Ann Intern Med 2005;143:697-706.
23. Trussell J, Wynn LL. Reducing unintended pregnancy in the United States. Contraception 2008;77:1-5.
24. Maguire K, Westhoff C. The state of hormonal contraception today: established and emerging noncontraceptive health benefits. Am J Obstet Gynecol 2011;205:S4-8.
25. Britt K, Short R. The plight of nuns: hazards of nulliparity. Lancet 2011 Dec 7 [Epub ahead of print].
26. Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstet Gynecol 2011;117:33-40.
27. Oddens BJ. Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning, and sterilization among 1466 women. Contraception 1999;59:277-86. (Pubitemid 29406028)
28. Dempsey AR, Johnson SS, Westhoff CL. Predicting oral contraceptive continuation using the transtheoretical model of health behavior change. Perspect Sex Reprod Health 2011;43: 23-9.
29. Nelson AL, Rezvan A. A pilot study of women's knowledge of pregnancy health risks: implications for contraception. Contraception 2012;85:78-82.
30. Lee J, Jezewski MA. Attitudes toward oral contraceptive use among women of reproductive age: a systematic review. ANS Adv Nurs Sci 2007;30:E85-103.
31. Hamani Y, Sciaki-Tamir Y, Deri-Hasid R, Miller-Pogrund T, Milwidsky A, Haimov-Kochman R. Misconceptions about oral contraception pills among adolescents and physicians. Hum Reprod 2007;22:3078-83. (Pubitemid 351696767)
32. Furedi A. The public health implications of the 1995 'pill scare.' Hum Reprod Update 1999;5:621-6. (Pubitemid 30034884)
33. Farmer RD, Williams TJ, Simpson EL, Nightingale AL. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of general practice research database. BMJ 2000;321:477-9. (Pubitemid 30623601)